Literature DB >> 18998139

Successful treatment of SAPHO syndrome with an oral bisphosphonate.

Jiro Ichikawa1, Eiichi Sato, Hirotaka Haro, Takashi Ando, Singo Maekawa, Yoshiki Hamada.   

Abstract

The etiology of the synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome remains unclear and treatment with various drugs for SAPHO syndrome often fails. But recently the effectiveness of intravenous bisphosphonates (BPs) for SAPHO syndrome has been reported in many cases and the use of intravenous BPs as first choice drug has been thought to be effective. On the other hand, serious side effects of intravenous BPs were reported in some cases. This is the first reported case of successful treatment of SAPHO syndrome with an oral BPs, the use of which is safer and more practical than intravenous BPs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18998139     DOI: 10.1007/s00296-008-0760-z

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  12 in total

Review 1.  Breast cancer: bisphosphonate therapy for metastatic bone disease.

Authors:  Jean-Jacques Body
Journal:  Clin Cancer Res       Date:  2006-10-15       Impact factor: 12.531

2.  Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study.

Authors:  Shinji Uchida; Tadaaki Taniguchi; Takafumi Shimizu; Taro Kakikawa; Kotoba Okuyama; Masahiko Okaniwa; Hironori Arizono; Koichi Nagata; Arthur C Santora; Masataka Shiraki; Masao Fukunaga; Tatsushi Tomomitsu; Yasuo Ohashi; Toshitaka Nakamura
Journal:  J Bone Miner Metab       Date:  2005       Impact factor: 2.626

3.  The usefulness of bone remodelling markers in predicting the efficacy of pamidronate treatment in SAPHO syndrome.

Authors:  E Solau-Gervais; M Soubrier; I Gerot; L Grange; X Puechal; C Sordet; J Sibilia; B Duquesnoy
Journal:  Rheumatology (Oxford)       Date:  2005-10-25       Impact factor: 7.580

Review 4.  Pharmacological management of SAPHO syndrome.

Authors:  Ignazio Olivieri; Angela Padula; Carlo Palazzi
Journal:  Expert Opin Investig Drugs       Date:  2006-10       Impact factor: 6.206

Review 5.  Dosing regimens and main adverse events of bisphosphonates.

Authors:  J J Body
Journal:  Semin Oncol       Date:  2001-08       Impact factor: 4.929

6.  Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.

Authors:  Aristotle Bamias; Efstathios Kastritis; Christina Bamia; Lia A Moulopoulos; Ioannis Melakopoulos; George Bozas; Vassiliki Koutsoukou; Dimitra Gika; Athanasios Anagnostopoulos; Christos Papadimitriou; Evagelos Terpos; Meletios A Dimopoulos
Journal:  J Clin Oncol       Date:  2005-12-01       Impact factor: 44.544

7.  Pamidronate in the treatment of childhood SAPHO syndrome.

Authors:  C Kerrison; J E Davidson; A G Cleary; M W Beresford
Journal:  Rheumatology (Oxford)       Date:  2004-07-06       Impact factor: 7.580

8.  Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases.

Authors:  Salvatore L Ruggiero; Bhoomi Mehrotra; Tracey J Rosenberg; Stephen L Engroff
Journal:  J Oral Maxillofac Surg       Date:  2004-05       Impact factor: 1.895

9.  Effect of liposomal and free bisphosphonates on the IL-1 beta, IL-6 and TNF alpha secretion from RAW 264 cells in vitro.

Authors:  N Pennanen; S Lapinjoki; A Urtti; J Mönkkönen
Journal:  Pharm Res       Date:  1995-06       Impact factor: 4.200

10.  Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.

Authors:  Lee S Rosen; David Gordon; Mary Kaminski; Anthony Howell; Andrew Belch; John Mackey; Justus Apffelstaedt; Mohamad A Hussein; Robert E Coleman; Dirk J Reitsma; Bee-Lian Chen; John J Seaman
Journal:  Cancer       Date:  2003-10-15       Impact factor: 6.860

View more
  10 in total

Review 1.  SAPHO syndrome--a pictorial assay.

Authors:  Lokesh Khanna; Georges Y El-Khoury
Journal:  Iowa Orthop J       Date:  2012

2.  Successful treatment of SAPHO syndrome with adalimumab: a case report.

Authors:  Ivan Castellví; Maria Bonet; Jose A Narváez; Jose C Molina-Hinojosa
Journal:  Clin Rheumatol       Date:  2010-05-06       Impact factor: 2.980

3.  Successful treatment of SAPHO syndrome with severe spinal disorder using entercept: a case study.

Authors:  L L Zhang; J X Zhao; X Y Liu
Journal:  Rheumatol Int       Date:  2011-04-03       Impact factor: 2.631

4.  Successful treatment of resistant SAPHO syndrome with anti-TNF therapy.

Authors:  Shayma Lamya Hampton; Hazem Youssef
Journal:  BMJ Case Rep       Date:  2013-01-25

Review 5.  The effectiveness of treatments for patients with SAPHO syndrome: a follow-up study of 24 cases from a single center and review of literature.

Authors:  Hong Huang; Zhuoli Zhang; Juan Zhao; Yanjie Hao; Wei Zhou
Journal:  Clin Rheumatol       Date:  2020-08-13       Impact factor: 2.980

6.  A case of autoinflammatory skin and bone disease flared by a change in osteoporosis management.

Authors:  Larry K Heard; Vanessa N Richardson; Caroline M Lewis; Loretta S Davis
Journal:  JAAD Case Rep       Date:  2017-03-10

7.  SAPHO Syndrome: Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis.

Authors:  Kiyofumi Hagiwara; Yasuhiro Suyama; Kunihiko Fukuda
Journal:  Intern Med       Date:  2017-03-01       Impact factor: 1.271

Review 8.  Cutibacterium acnes as an Opportunistic Pathogen: An Update of Its Virulence-Associated Factors.

Authors:  Constance Mayslich; Philippe Alain Grange; Nicolas Dupin
Journal:  Microorganisms       Date:  2021-02-02

9.  Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome of femoral neoplasm-like onset: a case-based review.

Authors:  Cheng Qiu; Lin Cheng; Haodong Hou; Tianyi Liu; Bohan Xu; Xing Xiao; Zhankui Wang; Qing Wang
Journal:  J Int Med Res       Date:  2021-12       Impact factor: 1.671

Review 10.  SAPHO syndrome: pathogenesis, clinical presentation, imaging, comorbidities and treatment: a review.

Authors:  Hanna Przepiera-Będzak; Marek Brzosko
Journal:  Postepy Dermatol Alergol       Date:  2020-07-23       Impact factor: 1.837

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.